IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies

Recruiting

Phase 2

PanzygaIVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies

Sponsor:

Endeavor Health

Code:

NCT04153422

Conditions

Small Fiber Neuropathy

Autoimmune Small Fiber Neuropathy

Inflammatory Polyneuropathy

Immune-Mediated Neuropathy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Panzyga IVIG

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-03. This information was provided to ClinicalTrials.gov by Endeavor Health on 2026-01-09.